|
Halo nevus, rather than
vitiligo, is a typical dermatologic finding of turner's syndrome:
clinical, genetic, and immunogenetic study in 72 patients.
J Am Acad Dermatol. 2004 Sep;51(3):354-8.
Turner's syndrome
(TS) is a genetic disorder caused by numeric and/or structural
abnormalities of the X chromosome; it is characterized by short stature,
gonadal dysgenesis, and frequently by webbed neck, cubitus valgus, and
lymphedema at birth. TS has been associated with several cutaneous
abnormalities including an increased frequency of pigmented nevi, but
few reports consider nevi in detail. Halo nevus (HN) is clinically
defined as a melanocytic nevus surrounded by a halo of depigmentation.
Vitiligo, a dermatologic disorder characterized by the presence of
depigmented patches on the skin, has been described in the list of
cutaneous findings associated with TS. The aim of this study was to
determine the prevalence of HN and vitiligo in TS and to evaluate if a
correlation between major histocompatibility complex genes, karyotype,
autoimmunity, therapies, and the presence of HN exists. Of the 72
patients with TS examined, 13 had HN, a prevalence of 18.05%, which was
significantly higher than in our control group (1%; P=.000001). On the
contrary, only 2 patients with TS (2.77%, P=not significant) had
vitiligo. By comparing the distribution of HLA class I alleles between
patients with TS who did (13 of 72) and did not (59 of 72) have HN, we
observed a significantly higher frequency of HLA-Cw6 in patients with TS
and HN than in those without HN (26.92% vs 6.78%, respectively; P=.0067;
odds ratio=5.06). The study of HLA class II genomic polymorphisms showed
that the DRB1(*)0701 and DQB1*02 alleles for patients with TS and HN
were overrepresented when compared with those without HN (34.61% vs
11.86%, respectively, P=.0078, odds ratio=3.93; and 34.61% vs 19.49%,
respectively, P=.1386, odds ratio=2.19). In conclusion, this study is
the first to demonstrate an increased prevalence of HN for patients with
TS. Furthermore, the data suggest that a HN putative susceptibility gene
in TS is located close to the HLA-C locus.
Turner syndrome: diagnosis and management.
Am Fam Physician. 2007 Aug 1;76(3):405-10.
Turner syndrome
occurs in one out of every 2,500 to 3,000 live female births. The
syndrome is characterized by the partial or complete absence of one X
chromosome (45,X karyotype). Patients with Turner syndrome are at risk
of congenital heart defects (e.g., coarctation of aorta, bicuspid aortic
valve) and may have progressive aortic root dilatation or dissection.
These patients also are at risk of congenital lymphedema, renal
malformation, sensorineural hearing loss, osteoporosis, obesity,
diabetes, and atherogenic lipid profile. Patients usually have normal
intelligence but may have problems with nonverbal, social, and
psychomotor skills. Physical manifestations may be subtle but can
include misshapen ears, a webbed neck, a broad chest with widely spaced
nipples, and cubitus valgus. A Turner syndrome diagnosis should be
considered in girls with short stature or primary amenorrhea. Patients
are treated for short stature in early childhood with growth hormone
therapy, and supplemental estrogen is initiated by adolescence for
pubertal development and prevention of osteoporosis. Almost all women
with Turner syndrome are infertile, although some conceive with assisted
reproduction.
Turner syndrome and the heart: cardiovascular complications and
treatment strategies.Am
J Cardiovasc Drugs. 2002;2(6):401-413.
Turner syndrome is
a condition usually associated with reduced final height, gonadal
dysgenesis, and thus insufficient circulating levels of female sex
steroids, and infertility. A number of other signs and symptoms are seen
more frequently with the syndrome. With respect to cardiac function,
congenital malformations of the heart and the great vessels,
hypertension and ischemic heart disease, and increased risk of aortic
dissection are all conditions that the pediatrician or the physician
caring for females with Turner syndrome should keep in mind. Many girls
and adolescents with Turner syndrome receive growth hormone (GH)
treatment, which has so far been an effective and well-tolerated
therapy. Nevertheless, because of the experience from acromegaly, the
physician should monitor blood pressure and perform echocardiography,
together with clinical examinations by a cardiologist at regular
intervals. During adulthood most women with Turner syndrome are faced
with premature menopause and the need for female hormone replacement
therapy (HRT). During clinical evaluation of girls and women with Turner
syndrome, these conditions and complications should be kept under
surveillance. Here the cardiovascular complications of Turner syndrome
are reviewed. The risk of congenital heart defects such as bicuspid
aortic valves, aortic coarctation, other valve abnormalities, and septal
defect is increased. Likewise, the risk of aortic dissection at a young
age is increased, as is the risk of hypertension, ischemic heart
disease, and stroke. GH therapy does not seem to adversely affect the
heart, although longer-term follow-up studies are needed. In short-term
studies, HRT lowers blood pressure, while any effect on the risk of
ischemic heart disease has not been evaluated. Treatment with GH and HRT
are discussed in relation to the heart and great vessels. Presently, the
pathophysiology of the congenital cardiovascular malformation in Turner
syndrome is unexplained, although different theories exist.
Recommendations for clinical practice are given, including life-long
surveillance of cardiac function, aortic diameter and blood pressure.
Follicles are found in the ovaries of adolescent girls with Turner's
syndrome.
J Clin Endocrinol Metab. 2002;87(8):3618-23.
Infertility
caused by ovarian failure is a characteristic feature in Turner's
syndrome. Spontaneous pregnancies are seen in 2-5% of these women, and
up to 30% have at least some pubertal development, indicating the
presence of follicles in their ovaries in adolescence. It has not been
clear at which age the follicles disappear. We analyzed the numbers and
densities of follicles in ovarian cortical tissue from nine adolescent
girls with Turner's syndrome who came to our clinics after having been
informed about the study, with an aim to preserve ovarian tissue for
possible infertility treatment later in life. A quarter to one whole
ovary was laparoscopically removed for the procedure. Follicles were
seen in the biopsy tissue in eight of nine subjects from whom ovarian
tissue was laparoscopically obtained, the highest numbers being seen in
the youngest girls and in those with mosaicism. In one 17-yr-old girl,
no ovarian tissue was found. Follicle density was correlated with serum
levels of FSH; individuals with the lowest FSH levels had the highest
follicle density. One to 190 follicles were counted in the approximately
0.1-2.0 mm(3) of tissue analyzed, giving a density of 1.5-499
follicles/mm(3) of ovarian cortical tissue. Girls up to the age of 17
had primordial follicles in their ovaries. Three girls, two aged 15 yr
and one aged 19, had only secondary follicles, with many being atretic.
Our finding that adolescent girls with Turner's syndrome still have
follicles in their ovarian cortical tissue raises the possibility of
future fertility through cryopreservation of ovarian tissue. However,
before such procedures can be recommended for clinical management, it is
essential that future studies be performed to determine whether the
oocytes retrieved from girls with Turner's syndrome have a normal
chromosomal complement.
|